Andere talen Organon & Co.

Aandelen

OGN

US68622V1061

Geschatte realtime Cboe BZX Andere beurzen 16:08:12 23-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
21,72 ^USD	-1,12%		+1,03%	+50,77%

08/05	Organon meldt de prijs van $ 1 miljard aan senior notes	MT
07/05	Organon is van plan Secured, Unsecured Senior Notes aan te bieden voor een totaal van $1 miljard	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Organon & Co and Organon Foreign Debt Co-Issuer B.V Closes Their Previously Announces Private Offering of $500 Million of 6.750% Senior Secured Notes Due 2034 and $500 Million of 7.875% Senior Unsecured Notes Due 2034	17/05
Organon Reports Pricing of $1 Billion Senior Notes Offering	08/05
Organon Announces Pricing of $1.0 Billion Senior Notes Offering	08/05
Organon & Co. and Organon Foreign Debt Co-Issuer B.V. Announces Pricing of $1.0 Billion Senior Notes Offering	08/05
Organon Plans Offerings of Secured, Unsecured Senior Notes Totaling $1 Billion	07/05
Organon Announces Proposed $1.0 Billion Senior Notes Offering	07/05
Organon & Co. and Organon Foreign Debt Co-Issuer BV Announces Proposed $1.0 Billion Senior Notes Offering	07/05
Organon : Q1 2024 Transcript	03/05
Organon's Q1 Adjusted Earnings, Revenue Rise; 2024 Revenue Guidance, Quarterly Dividend Maintained	02/05
Organon : Q1 2024 Earnings Presentation	02/05
Organon : 2024 Annual Meeting of Shareholders	02/05
Earnings Flash (OGN) ORGANON & CO. Reports Q1 Revenue $1.62B, vs. Street Est of $1.56B	02/05
Organon: Q1 Earnings Snapshot	02/05
Earnings Flash (OGN) ORGANON & CO. Reports Q1 EPS $1.22, vs. Street Est of $0.93	02/05
Organon Reports Results for the First Quarter Ended March 31, 2024	02/05
Organon & Co. Reports Earnings Results for the First Quarter Ended March 31, 2024	02/05
Organon & Co. Provides Earnings Guidance for the Year 2023	02/05
Organon & Co Declares Quarterly Dividend on Common Stock, Payable on June 13, 2024	02/05
El estudio clínico comparativo de fase 3 del candidato a biosimilar de Prolia ® y Xgeva ® (denosumab) HLX14 alcanzó los criterios de valoración primarios	08/04
Klinische Phase-3-Vergleichsstudie zwischen Prolia ® und Xgeva ® (Denosumab) - Biosimilar-Kandidat HLX14 erreicht primäre Endpunkte	08/04

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Organon & Co.

Aandelen

OGN

US68622V1061

Andere talen

Filters